Smyd1: Implications for novel approaches in rhabdomyosarcoma therapy
Janine Berkholz1, Angelika Schmitt2, Annunziata Fragasso2
1Charité - University Medicine Berlin, Institute of Physiology, Charitéplatz 1, D-10117, Berlin, Germany.
Abstract:
Rhabdomyosarcoma (RMS), a tumor that consists of poorly differentiated skeletal muscle cells, is the most common soft-tissue sarcoma in children. Despite considerable progress within the last decades, therapeutic options are still limited, warranting the need for novel approaches. Recent data suggest deregulation of the Smyd1 protein, a sumoylation target as well as H3K4me2/3 methyltransferase and transcriptional regulator in myogenesis, and its binding partner skNAC, in RMS cells. Here, we show that despite the fact that most RMS cells express at least low levels of Smyd1 and skNAC, failure to upregulate expression of these genes in reaction to differentiation-promoting signals can always be observed. While overexpression of the Smyd1 gene enhances many aspects of RMS cell differentiation and inhibits proliferation rate and metastatic potential of these cells, functional integrity of the putative Smyd1 sumoylation motif and its SET domain, the latter being crucial for HMT activity, appear to be prerequisites for most of these effects. Based on these findings, we explored the potential for novel RMS therapeutic strategies, employing small-molecule compounds to enhance Smyd1 activity. In particular, we tested manipulation of (a) Smyd1 sumoylation, (b) stability of H3K4me2/3 marks, and (c) calpain activity, with calpains being important targets of Smyd1 in myogenesis. We found that specifically the last strategy might represent a promising approach, given that suitable small-molecule compounds will be available for clinical use in the future.
Insights
Smyd1 protein is crucial for rhabdomyosarcoma (RMS) cell differentiation. Enhancing Smyd1 activity, particularly targeting calpain activity, shows promise for novel pediatric soft-tissue sarcoma therapies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Rhabdomyosarcoma (RMS) is the most common pediatric soft-tissue sarcoma with limited therapeutic options.
- Smyd1 protein, a regulator of myogenesis, and its partner skNAC are implicated in RMS.
- Dysregulation of Smyd1 and skNAC expression is observed in RMS cells.
Purpose of the Study:
- To investigate the role of Smyd1 in RMS cell differentiation and proliferation.
- To explore novel therapeutic strategies targeting Smyd1 activity in RMS.
- To evaluate the potential of small-molecule compounds to modulate Smyd1 function.
Main Methods:
- Analysis of Smyd1 and skNAC expression in RMS cells under differentiation-promoting conditions.
- Overexpression of Smyd1 to assess its effects on RMS cell differentiation, proliferation, and metastasis.
- Investigation of the functional importance of Smyd1's sumoylation motif and SET domain.
- Testing small-molecule compounds targeting Smyd1 sumoylation, H3K4me2/3 marks, and calpain activity.
Main Results:
- RMS cells fail to upregulate Smyd1 and skNAC in response to differentiation signals.
- Smyd1 overexpression enhances RMS cell differentiation, reduces proliferation, and inhibits metastasis.
- Functional Smyd1 sumoylation motif and SET domain are critical for its effects.
- Targeting calpain activity emerges as a promising therapeutic strategy.
Conclusions:
- Smyd1 plays a critical role in regulating RMS cell differentiation and behavior.
- Modulating Smyd1 activity, especially via calpain pathways, offers potential for new RMS therapies.
- Further development of small-molecule compounds is needed for clinical application.
Related Concept Videos
02:23Abnormal Proliferation
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...